|
|
||||||||
J Thorac Cardiovasc Surg 2006;132:1030-1036
© 2006 The American Association for Thoracic Surgery
Surgery for Acquired Cardiovascular Disease |
a Department of Thoracic and Cardiovascular Surgery, Rangueil University Hospital, Toulouse, France
b Department of Radiology, Rangueil University Hospital, Toulouse, France
e Department of Cardiology, Rangueil University Hospital, Toulouse, France
c Department of Epidemiology and Biostatistics, Toulouse University Hospital, Toulouse, France
d Department of Cardiology, Montauban General Hospital, Montauban, France.
Received for publication March 4, 2006; revisions received June 24, 2006; accepted for publication July 7, 2006. * Address for reprints: Hervé Rousseau, MD, Radiology Department, Rangueil University Hospital, TSA 50032, 1 Avenue Jean Poulhès, 31059 Toulouse, Cedex 9, France. (Email: rousseau.h{at}chu-toulouse.fr).
OBJECTIVE: We sought to determine the midterm results of endovascular repair of atherosclerotic aneurysms of the thoracic descending aorta by using second-generation, commercially available stent grafts.
METHODS: Between 1996 and 2005, 45 patients (mean age, 68 ± 11 years) with aneurysms of the descending thoracic aorta underwent endovascular repair. Aortic dissections, penetrating ulcers, and traumatisms were excluded. The mean follow-up was 24.7 ± 21.6 months (maximum, 6.7 years).
RESULTS: No patients died, and no conversion to surgical intervention was required during the procedures. Three (6.7%) patients died during the first month, and 6 (14.7%) died later on. The main complications were strokes (13.3%), vascular access complications (8.9%), aortic complications (6.6%), paraplegia (4.4%), and sudden deaths (4.4%). Nineteen (42%) primary endoleaks were encountered: 3 required reinterventions, 15 spontaneously thrombosed, and 1 patient died. Except for 2 sudden unexplained deaths, no aortic complications were observed after 1 month. Actuarial survival estimates at 1, 3, and 5 years were 87.6% ± 5.3%, 76.9% ± 7.4%, and 70.6% ± 9.2%, respectively. Actuarial freedom from death related to the treated aortic disease was 94.3% ± 4.0%, 94.3% ± 4.0%, and 86.4% ± 8.4% at 1, 3, and 5 years, respectively. Aspirin status of greater than 3 (P = .005), high aortic diameter (P = .007), and long covered lengths (P = .02) were determinant for mortality. Actuarial freedom from complication was 62.6% ± 7.7%, 58.9% ± 8.1%, and 58.9% ± 8.1% at 1, 3, and 5 years, respectively. The location of the aneurysm (P = .05) and a high aortic diameter (P = .04) were both determinants for endoleaks.
CONCLUSIONS: Stent grafting of atherosclerotic aneurysm of the thoracic descending aorta is safe and effective. Further studies are mandatory to determine the most relevant indications and the long-term efficacy of such treatment.
This article has been cited by other articles:
![]() |
A. Marui, T. Mochizuki, T. Koyama, and N. Mitsui Degree of fusiform dilatation of the proximal descending aorta in type B acute aortic dissection can predict late aortic events. J. Thorac. Cardiovasc. Surg., November 1, 2007; 134(5): 1163 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Bakaeen, J. S. Coselli, S. A. LeMaire, and J. Huh Continued Aortic Aneurysmal Expansion After Thoracic Endovascular Stent-Grafting Ann. Thorac. Surg., September 1, 2007; 84(3): 1007 - 1008. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |